Merck & Co. entered a multi-year collaboration with Guardant Health to leverage the Guardant Infinity Smart liquid biopsy platform to advance and commercialize its oncology portfolio. The deal underscores Merck’s commitment to precision oncology and could accelerate biomarker-driven clinical trials and diagnostic integration for its drug candidates.